全文获取类型
收费全文 | 78332篇 |
免费 | 4936篇 |
国内免费 | 281篇 |
专业分类
耳鼻咽喉 | 1126篇 |
儿科学 | 2214篇 |
妇产科学 | 1461篇 |
基础医学 | 8733篇 |
口腔科学 | 1554篇 |
临床医学 | 7907篇 |
内科学 | 16245篇 |
皮肤病学 | 1183篇 |
神经病学 | 7486篇 |
特种医学 | 2828篇 |
外国民族医学 | 5篇 |
外科学 | 13582篇 |
综合类 | 1085篇 |
一般理论 | 100篇 |
预防医学 | 6647篇 |
眼科学 | 1438篇 |
药学 | 4924篇 |
中国医学 | 117篇 |
肿瘤学 | 4914篇 |
出版年
2023年 | 419篇 |
2022年 | 698篇 |
2021年 | 1869篇 |
2020年 | 996篇 |
2019年 | 1656篇 |
2018年 | 1940篇 |
2017年 | 1394篇 |
2016年 | 1444篇 |
2015年 | 1574篇 |
2014年 | 2394篇 |
2013年 | 3468篇 |
2012年 | 5183篇 |
2011年 | 5393篇 |
2010年 | 2961篇 |
2009年 | 2600篇 |
2008年 | 4733篇 |
2007年 | 5028篇 |
2006年 | 4901篇 |
2005年 | 4813篇 |
2004年 | 4591篇 |
2003年 | 4220篇 |
2002年 | 3931篇 |
2001年 | 814篇 |
2000年 | 737篇 |
1999年 | 861篇 |
1998年 | 833篇 |
1997年 | 750篇 |
1996年 | 672篇 |
1995年 | 574篇 |
1994年 | 574篇 |
1993年 | 493篇 |
1992年 | 557篇 |
1991年 | 563篇 |
1990年 | 475篇 |
1989年 | 449篇 |
1988年 | 402篇 |
1987年 | 395篇 |
1986年 | 394篇 |
1985年 | 495篇 |
1984年 | 538篇 |
1983年 | 452篇 |
1982年 | 589篇 |
1981年 | 541篇 |
1980年 | 501篇 |
1979年 | 280篇 |
1978年 | 343篇 |
1977年 | 310篇 |
1976年 | 248篇 |
1975年 | 255篇 |
1973年 | 229篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
61.
62.
63.
64.
In vivo voltammetry at chronically implanted carbon paste electrodes in unrestrained rats is a particularly useful technique for evaluating neurochemical changes during spontaneous behaviour, or behaviour under experimental control. A 3 peak signal is observed in the striatum; most recently the consensus view has attributed these peaks to ascorbic acid (AA), uric acid (UA) and homovanillic acid (HVA) in ascending order of oxidation potential. We have used a pharmacological approach, combined with in vivo dialysis, to further elucidate the nature of the contributing species. Allopurinol, an inhibitor of xanthine oxidase, and thus of uric acid production, has previously been reported to abolish peak 2. We now report, using dialysis, that it selectively depletes UA in the extracellular fluid (ECF). Pargyline, a monoamine oxidase inhibitor, reduces peak 3 transiently (max. 60%) as expected, however it results in a more sustained reduction in ECF HVA (max. 100%). It also increases peak 1 (max. 75%) and decreases peak 2 (max. 40%), although changes in ECF AA and UA measured by dialysis and HPLC are minimal. Pargyline does however reduce ECF 5-hydroxyindoleacetic acid by 65%. We conclude that, using linear sweep voltammetry at chronically implanted paste electrodes: (a) one or more substances in addition to AA can contribute to peak 1; dopamine can do so in some situations; (b) 5-hydroxyindoleacetic acid, as well as UA, contributes to peak 2; its contribution is about one third that of the latter; and (c) one or more substances in addition to HVA can contribute to peak 3. 3-Methoxytyramine can do so. Since this is another methylated metabolite of dopamine, this does not prevent the use of peak 3 as an index of dopamine metabolism, and may extend its usefulness to situations where monoamine oxidase is inhibited. 相似文献
65.
N. E. McCarthy H. A. Jones N. A. Marks R. J. Shiner P. W. Ind H. O. Al-Hassi N. R. English C. M. Murray J. R. Lambert S. C. Knight A. J. Stagg 《Clinical and experimental allergy》2007,37(1):72-82
Background Dendritic cells (DC) mediate inflammation in rodent models of allergic airway disease, but the role played by human respiratory‐tract DC (hRTDC) in atopic asthma remains poorly defined. Recent data suggest that CD1 antigen presentation by hRTDC may contribute to asthma pathogenesis. Objective To investigate the influence of hRTDC on the balance between atopy and allergic asthma in human subjects and to determine whether CD1 expression by hRTDC is modulated during asthmatic inflammation. Methods Sputum cells were induced from steroid‐naïve, allergen‐challenged and allergen‐naïve subjects (atopic asthmatics, atopic non‐asthmatics and non‐atopic controls). hRTDC were identified using monoclonal antibody labelling and analysis by flow cytometry. Results hRTDC stained HLA‐DR+ (negative for markers of other cell lineages) were predominantly myeloid and comprised ∼0.5% of viable sputum cells. Sputum cells were potent stimulators of allogeneic CD4+ naïve T cells and enrichment/depletion experiments correlated stimulatory potency with DC numbers. Sputum contained cells that exhibited typical dendritic morphology when analysed by electron microscopy. Myeloid hRTDC were endocytically active, but uptake of FITC‐dextran was enhanced in cells from asthmatics (P<0.001). Despite their increased endocytic capacity, asthmatic myeloid hRTDC appeared mature and expressed increased levels of maturation markers (P<0.05–P<0.001), CD1c, CD1d and langerin (P<0.05). CD1c expression by asthmatic myeloid hRTDC was enhanced upon in vivo allergen challenge (three to ninefold within 24 h; P<0.05). CD11c−CD123high hRTDC were only detected in asthmatic sputum and were increased in number following allergen challenge. Conclusion Despite limited cell numbers, it proved possible to analyse human RTDC in induced sputum, providing evidence that increased antigen uptake and enhanced CD1 presentation by activated hRTDC may contribute to allergic airway disease. CD1 presentation by hRTDC in atopic asthma may therefore constitute a novel target for future intervention strategies. 相似文献
66.
Margaret Sullivan Pepe Ziding Feng Gary Longton Joseph Koopmeiners 《Statistics in medicine》2009,28(5):762-779
Development of a disease screening biomarker involves several phases. In phase 2 its sensitivity and specificity is compared with established thresholds for minimally acceptable performance. Since we anticipate that most candidate markers will not prove to be useful and availability of specimens and funding is limited, early termination of a study is appropriate, if accumulating data indicate that the marker is inadequate. Yet, for markers that complete phase 2, we seek estimates of sensitivity and specificity to proceed with the design of subsequent phase 3 studies. We suggest early stopping criteria and estimation procedures that adjust for bias caused by the early termination option. An important aspect of our approach is to focus on properties of estimates conditional on reaching full study enrollment. We propose the conditional‐UMVUE and contrast it with other estimates, including naïve estimators, the well‐studied unconditional‐UMVUE and the mean and median Whitehead‐adjusted estimators. The conditional‐UMVUE appears to be a very good choice. Copyright © 2008 John Wiley & Sons, Ltd. 相似文献
67.
In the differential clinical diagnosis of mammary neoplasms, adenocarcinoma can safely be excluded only after biopsy and microscopic study.In a series of 177 cases of mammary cancer treated by surgery with x-ray therapy, 30.4 per cent of the patients are alive three years or more after treatment; 18 per cent five years or longer.Only one of every four patients presents herself with a lesion still within the breast. Exclusive of Group I this results in a cure in 86.1 per cent in Group II and 15.4 per cent in Group III. The mortality rate then increases five and one-half times as spread occurs beyond the breast.The results of irradiation therapy for curative purposes in recurrent or metastatic mammary adenocarcinoma are poor.
Stage | Patients Treated | Per Cent Cures |
I | 1 | 100.0 |
II and IIa | 40 | 86.1 |
III and IIIa | 130 | 15.4 |